November 21, 2016 - By Dolores Ford · 0 Comments
ADMA BIOLOGICS (NASDAQ:ADMA) institutional sentiment decreased to 0.75 in 2016 Q2. Its down -2.85, from 3.6 in 2016Q1. The ratio worsened, as 18 investment managers opened new and increased equity positions, while 5 sold and decreased their equity positions in ADMA BIOLOGICS. The investment managers in our partner’s database now own: 16.07 million shares, up from 6.92 million shares in 2016Q1. Also, the number of investment managers holding ADMA BIOLOGICS in their top 10 equity positions was flat from 1 to 1 for the same number . Sold All: 2 Reduced: 3 Increased: 12 New Position: 6.
ADMA Biologics, Inc. is a late-stage biopharmaceutical firm that develops, makes and intends to market specialty plasma biologics for the treatment and prevention of infectious diseases. The company has a market cap of $68.01 million. The Firm is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. It currently has negative earnings. The Company’s divisions include Plasma Collection Centers, which includes its activities in Georgia; Research and Development, which includes its plasma development activities in New Jersey, and Corporate.
About 17,159 shares traded hands. ADMA Biologics Inc (NASDAQ:ADMA) has declined 24.73% since April 19, 2016 and is downtrending. It has underperformed by 28.59% the S&P500.
According to Zacks Investment Research, “ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases. The Company’s target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease or who may be immune-suppressed for medical reasons. Its lead product candidate, RI-002, which is in Phase III clinical trial, is intended for the treatment of primary immune deficiency disease. ADMA Biologics, Inc. is headquartered in Ramsey, New Jersey.”
Aisling Capital Llc holds 5.07% of its portfolio in ADMA Biologics Inc for 3.61 million shares. Consonance Capital Management Lp owns 1.27 million shares or 1.07% of their US portfolio. Moreover, Broadfin Capital Llc has 0.64% invested in the company for 1.11 million shares. The New York-based Iguana Healthcare Management Llc has invested 0.3% in the stock. Perceptive Advisors Llc, a New York-based fund reported 398,394 shares.#img1#
Ratings analysis reveals 0 of ADMA Biologics’s analysts are positive. Out of 2 Wall Street analysts rating ADMA Biologics, 0 give it “Buy”, 0 “Sell” rating, while 2 recommend “Hold”. ADMA was included in 4 notes of analysts from September 9, 2015. Raymond James initiated the shares of ADMA in a report on Wednesday, September 9 with “Strong Buy” rating. Raymond James downgraded the stock to “Market Perform” rating in Monday, August 1 report. The firm has “Hold” rating by Maxim Group given on Monday, August 1. The rating was maintained by Maxim Group with “Buy” on Thursday, September 17.
ADMA Biologics, Inc., incorporated on June 2, 2006, is a late-stage biopharmaceutical firm that develops, makes and intends to market specialty plasma biologics for the treatment and prevention of infectious diseases. The Firm is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. The Company’s divisions include Plasma Collection Centers, Research and Development, and Corporate. The Plasma Collection Centers segment includes the Company’s activities in Georgia. The Research and Development segment includes the Company’s plasma development activities in New Jersey. The Company’s targeted patient populations include immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. The Company’s product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. The Company’s lead product candidate, RI-002, is intended for the treatment of primary immune deficiency disease (PIDD) and has completed a pivotal Phase III clinical study.
More recent ADMA Biologics Inc (NASDAQ:ADMA) news were published by: Marketwatch.com which released: “Plus the latest data from Realtor.com on 21 home markets across the US” on November 18, 2013. Also Quotes.Wsj.com published the news titled: “News ADMA Biologics Inc.ADMA” on February 11, 2011. Prnewswire.com‘s news article titled: “SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …” with publication date: August 01, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Dolores Ford